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Perfluorooctanoic acid (PFOA, or C8) is a 
perfluorinated compound (PFC) that does not 
occur naturally but was introduced in the envi-
ronment after World War II. PFCs are fluoro-
carbons with at least one additional atom or 
functional group; PFOA has a carboxylic acid 
group (C7F15COOH). Most people tested in 
the United States have PFOA in their serum 
(measured via perfluoro octanoate, the disassoci-
ated ion of PFOA), with a median of 4 ng/mL, 
but the source of exposure is not clear (Calafat 
et al. 2007b). PFOA has also been detected 
in the serum of populations in a number of 
industrialized countries (Fromme et al. 2009; 
Kannan et al. 2004; Lau et al. 2007). Limited 
data suggest that PFOA in water systems 
may result from wastewater treatment plants, 
which concentrate PFOA (Becker et al. 2008; 
Pistocchio and Loos 2009). Levels of PFOA 
in the serum appear to be decreasing in the 
U.S. population, because some large users have 
curtailed emissions (Calafat et al. 2007b; Olsen 
et al. 2007b).
Determinants of PFOA in the general 
population are known to include age (higher 
at younger and older ages), sex (males higher), 
and race (whites higher) (Calafat et al. 2007a, 
2007b; Emmett et al. 2006a; Steenland et al. 
2009a). However, none of these attributes are 
very strong predictors. For those living near a 
point source of contamination, contamination 
of drinking water has been identified as the 
major route of exposure (Emmett et al. 2006a; 
Hölzer et al. 2008; Steenland et al. 2009a).
PFOA has been used in the production 
of a wide variety of industrial and consumer 
products, such as Gore-Tex and Teflon. PFOA 
does not break down once in the environment, 
because of the strong carbon–fluorine bonds, 
leading to widespread buildup and bioaccu-
mulation. Two studies provide estimates of the 
half-life for PFOA in humans. In a study of 
26 retired fluorochemical production workers 
(mean years retired at initial blood collection, 
2.6), followed up for 5 years, the median half-
life was 3.4 years (Olsen et al. 2007a). In a 
study of 200 people who had been exposed via 
public water supplies and followed for 1 year 
after installation of filtration for the water sup-
plies, the median half-life was 2.3 years (Bartell 
et al. 2010). The latter estimate suffers from 
the short follow-up time (although this popu-
lation will be followed for 5 years), whereas the 
former suffers from small numbers and a lack 
of data at the time when exposure ceased.
PFOA is not metabolized in the body; its 
tissue distribution in humans is unknown, but 
studies in rats suggest it is likely to be pres-
ent primarily in the liver, kidney, and blood 
(Kennedy et al. 2004; Lau et al. 2007). It is 
easily absorbed via the gastrointestinal tract 
in rats. It is not lipophilic, unlike chlorinated 
hydrocarbons, but binds to serum albumin 
and is excreted primarily from the kidney. It is 
not directly genotoxic (Andersen et al. 2008).
There is a considerable amount of animal 
data on the health effects of PFOA, which has 
been summarized by others [Kennedy et al. 
2004; Lau et al. 2007; U.S. Environmental 
Protection Agency (EPA) 2005]. The rele-
vance of animal (primarily rodent) data for 
humans is controversial because of a much 
shorter half-life in rodents (measured in days) 
and the possible dependence of some animal 
toxicity on a peroxisome proliferation mech-
anism that is likely to be less important in 
humans (see below).
PFOA induces tumors of the testicles, liver, 
and pancreas in rodents (Biegel et al. 2001; 
Sibinski 1987; U.S. EPA 2005) via dietary 
intake, and there is some evidence it also 
increases mammary tumors (Sibinski 1987; 
U.S. EPA 2005). The lowest doses at which 
effects have been observed in these rodent stud-
ies appear to be several orders of magnitude 
higher than human doses from drinking water 
contaminated at a level of 1 ng/mL.
In its draft risk assessment, the U.S. EPA 
(2005) concluded that evidence was sugges-
tive that PFOA is carcinogenic in humans. In 
its review of that risk assessment, three of the 
four members of the EPA scientific advisory 
board concluded more strongly that PFOA 
was “likely to be carcinogenic in humans” 
(U.S. EPA 2006).
PFOA also reduces birth weight in mice 
and causes neonatal death in rats (Lau et al. 
2007; U.S. EPA 2005). In mice it decreases 
the B-cell and T-cell immune responses, and 
in rats it results in atrophy of the spleen and 
thymus, causes hepatomegaly, and decreases 
levels of cholesterol (Kennedy et al. 2004; 
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oBjective and sources: We reviewed the epidemiologic literature for PFOA.
data synthesis: Perfluorooctanoic acid (PFOA) does not occur naturally but is present in the 
serum of most residents of industrialized countries (U.S. median, 4 ng/mL). Drinking water is 
the primary route of exposure in some populations, but exposure sources are not well understood. 
PFOA has been used to manufacture such products as Gore-Tex and Teflon. PFOA does not break 
down in the environment; the human half-life is estimated at about 3 years. PFOA is not metabo-
lized in the body; it is not lipophilic. PFOA is not directly genotoxic; animal data indicate that it 
can cause several types of tumors and neonatal death and may have toxic effects on the immune, 
liver, and endocrine systems. Data on the human health effects of PFOA are sparse. There is rela-
tively consistent evidence of modest positive associations with cholesterol and uric acid, although 
the magnitude of the cholesterol effect is inconsistent across different exposure levels. There is some 
but much less consistent evidence of a modest positive correlation with liver enzymes. Most findings 
come from cross-sectional studies, limiting conclusions. Two occupational cohort studies do not 
provide consistent evidence for chronic disease; both are limited by sample size and reliance on mor-
tality data. Reproductive data have increased recently but are inconsistent, and any observed adverse 
effects are modest.
conclusions: Epidemiologic evidence remains limited, and to date data are insufficient to draw 
firm conclusions regarding the role of PFOA for any of the diseases of concern.
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Lau et al. 2007; Loveless et al. 2006). 
Several experimental studies have reported 
that PFCs impair thyroid hormone homeo-
stasis. Depression of serum triiodothyronine 
(T3) and/or thyroxine (T4) in PFOA- and 
PFOS-exposed rats and monkeys has been 
reported (Butenhoff et al. 2002; Lau et al. 
2007), but without an expected correspond-
ing elevation of thyroid-stimulating hor-
mone (TSH) through feedback stimulation 
of the  hypothalamic– pituitary– thyroid axis. 
However, it has been hypothesized these asso-
ciations could be an artifact of the use of ana-
log methods for assessment of free thyroid 
hormones and are absent if the equilibrium 
dialysis method is used (Chang et al. 2007; 
Lau et al. 2007).
One mechanism that has been proposed 
for these effects in rodents is peroxisome 
proliferation. In animals, PFOA is a strong 
peroxisome proliferator in the liver, and this 
proliferation has been shown to alter lipids, 
liver enzymes, and liver size (Kennedy et al. 
2004; Lau et al. 2007; Loveless et al. 2006). 
Proxisome proliferation and the resulting 
activation of a nuclear receptor [peroxisome 
 proliferator-activated receptor α (PPARα)] 
have also been proposed as a mechanism for 
tumor induction and for the immune and 
hormonal changes seen in rodents (Lau et al. 
2007). However, it is not known if this mech-
anism is relevant to humans, where peroxisome 
proliferation is generally less apparent (Dewitt 
et al. 2008; Klaunig et al. 2003). Furthermore, 
new observations question whether this mech-
anism is specifically relevant to liver carcino-
genesis in rodents (Guyton et al. 2009). This 
issue remains a subject of active investigation.
In the United States, the only popula-
tions exposed above background levels are 
occupational cohorts and two communities 
in Minnesota and West Virginia/Ohio. The 
two communities have been exposed via water 
contamination coming from adjacent indus-
trial plants; in Minnesota the mean PFOA was 
15 ng/mL as measured recently (Minnesota 
Department of Health 2009), whereas in the 
Mid-Ohio Valley the mean was 82 ng/mL 
in 2005 (Emmett et al. 2006a; Frisbee et al. 
2009; Steenland et al. 2009a). In the Mid-
Ohio Valley population, a great deal of health 
information and clinical chemistries, as well as 
serum measurements of PFCs, were gathered 
in a 2005–2006 survey of 69,000 residents of 
contaminated water districts. Descriptions of 
these data have been posted on the C8 Health 
Project web site (C8 Health Project 2009). 
PFOA is often correlated in human serum 
with another PFC, perfluorooctanesulfonic 
acid (PFOS). PFOS is also present in most 
human serum in the United States, with a 
median serum level of 21 ng/mL, although 
as with PFOA, the sources of this expo-
sure are poorly characterized (Calafat et al. 
2007a). Until recently PFOS has been used 
in the manufacture of Scotchgard (3M, St. 
Paul, MN) among other products (also until 
recently Scotchgard could emit PFOA as it 
degraded). Its half-life has been estimated at 
5.4 years (Olsen et al. 2007a). PFOS is also 
considered an animal carcinogen by U.S. EPA 
(2005). The epidemiology of PFOS is even 
more limited than that of PFOA. We do not 
review epidemiologic studies of PFOS per se 
here but mention findings for PFOS in stud-
ies that consider both PFOA and PFOS, to 
help interpret the PFOA results.
Lipids, Uric Acid, Diabetes, 
and Cardiovascular and 
Cerebrovascular Disease
Lipids. A positive association of PFOA with 
cholesterol was observed in six occupational 
studies (Costa et al. 2009; Olsen and Zobel 
2007; Olsen et al. 2000, 2003; Sakr et al. 
2007a, 2007b), three studies of a highly 
exposed community (Emmett et al. 2006b; 
Frisbee et al. in press; Steenland et al. 2009b), 
and one general population study (Nelson 
et al. 2010). Six of these studies showed a sta-
tistically significant association (at the p = 0.05 
level; all references in this article to statistical 
significance refer to p ≤ 0.05), whereas two 
occupational studies (Olsen and Zobel 2007; 
Olsen et al. 2000) and the smaller of the two 
community studies (Emmett et al. 2006b) 
did not. All of these studies were cross-sec-
tional except for three: Sakr et al. (2007b) 
had data on 454 workers with multiple PFOA 
and cholesterol measurements over an average 
of 10 years, Costa et al. (2009) had data on 
56 workers with such multiple measurements, 
and Olsen et al. (2003) had data on 174 work-
ers with two measurements. All three of these 
studies found a significant correlation over 
time between cholesterol and PFOA levels.
The risk of high cholesterol (≥ 240 mg/dL) 
also increased in relation to PFOA in some 
studies. For example, in Steenland et al. 
(2009b), comparing the highest quartile of 
PFOA versus the lowest yielded an odds ratio 
(OR) for high cholesterol of 1.38 [95% confi-
dence interval (CI), 1.28–1.50].
Many studies also showed positive rela-
tionships of PFOA with other lipids (i.e., low 
density lipoprotein cholesterol and triglycer-
ides), with the exception of high density lipo-
protein cholesterol, which was consistently not 
found to be associated with PFOA. Several 
studies (Frisbee et al. in press; Nelson et al. 
2010; Steenland et al. 2009b) also showed 
associations of lipids with PFOS that were 
similar in magnitude to those with PFOA. 
This finding raises the question of whether 
all PFCs are associated with increased lipids 
via some common mechanism. PFOA and 
PFOS are generally correlated in the serum; 
in two large studies, the correlations were 
0.31 (in a population with high-PFOA expo-
sure; Steenland et al. 2009b) and 0.65 (in a 
general population with background PFOA 
and PFOS exposures; Nelson et al. 2010). 
Generally, models including both compounds 
showed an attenuation of the association for 
both PFOA and PFOS, without one being 
clearly dominant. Only one study (Olsen et al. 
1999) addressed the effect of PFOS alone, 
an occupational cross-sectional study that 
showed a significant positive correlation with 
cholesterol at one plant but not at another.
Given the cross-sectional nature of 
most of these studies, it is not clear whether 
a) PFOA increases cholesterol and other lip-
ids; b) both PFOA and cholesterol are jointly 
affected by some other attribute, substance, 
or mechanism that causes their correlation; 
or c) high lipids might cause increased reten-
tion of PFOA in the body (reverse causality). 
Some evidence against this last hypothesis is 
provided by Steenland et al. (2009b), where 
those who had taken statins, associated with 
a large decrease in cholesterol, had PFOA 
levels similar to those who had not taken sta-
tins. The three longitudinal studies indicating 
that cholesterol and PFOA were related over 
time in subjects with repeated measurements 
(Costa et al. 2009; Olsen et al. 2003; Sakr 
et al. 2007b) strengthen the case for a causal 
relationship, although they do not preclude a 
relationship in which both PFOA and choles-
terol jointly covary with some biologic process 
that is also changing over time. 
The strength of the association of PFOA 
and cholesterol varied considerably by study, 
making interpretation even more problem-
atic: The lower the range of PFOA that was 
studied, the greater the change in cholesterol 
per unit change in PFOA. Thus, the stud-
ies of community populations report larger 
shifts in cholesterol per unit change in PFOA 
levels than do the occupational studies (which 
have higher exposures). Table 1 summarizes 
the changes in cholesterol associated with 
changes in PFOA. Assuming a linear rela-
tionship between the two (not always the 
case), the slope relating PFOA to cholesterol 
varied by two to three orders of magnitude. 
One possibility that might explain some of 
this discrepancy would be if the slope of an 
exposure–response relationship was steep at 
low PFOA levels and then flattened out, as 
might be the case, for example, if some bio-
logical pathways were saturated. There is a 
suggestion of such flattening in some stud-
ies (Frisbee et al. in press; Steenland et al. 
2009b). Most studies did not examine the 
exposure–response curve in detail.
The findings of associations between PFOA 
and increased cholesterol in humans contra-
dict what would be expected from animal 
studies, where PFOA decreases, not increases, 
serum lipids (Lau et al. 2007). However, as 
Steenland et al.
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also noted, it is not known whether peroxi-
some proliferation, the mechanism of action 
involved, is relevant to humans, where it is 
generally less apparent.
Uric acid. Uric acid is a natural product 
of purine metabolism and has both oxidant 
and antioxidant properties. There is consider-
able epidemiologic evidence that elevated uric 
acid is a risk factor for hypertension (Feig 
et al. 2008; Shankar et al. 2006).
Three cross-sectional studies report posi-
tive associations between PFOA and uric acid. 
Two are occupational studies [Costa et al. 
2009 (n = 160); Sakr et al. 2007a (n = 1,000)], 
and one is a community study [Steenland 
et al. 2010 (n = 55,000)]. No detailed results 
are provided in Sakr et al. (2007a). Costa et al. 
(2009), using a cross-sectional analysis, found 
mean uric acid levels of 6.29 µg/mL for 34 cur-
rently exposed workers, versus 5.73 µg/mL for 
34 matched nonexposed workers (p = 0.04). 
In addition, using repeated measures of both 
PFOA and uric acid over a 7-year period to 
perform a longitudinal analysis of this group 
(n = 56), Costa et al. (2009) found a signifi-
cant positive association between uric acid and 
PFOA; the two varied together over time.
In the cross-sectional study by Steenland 
et al. (2010), both PFOA and PFOS were 
significantly associated with uric acid. An 
increase from the lowest to highest decile of 
either PFOA or PFOS was associated with 
an increase of 0.2–0.3 mg/dL uric acid. 
Risk of abnormally high uric acid (hyper-
uricemia, defined as > 6.0 mg/dL for women, 
> 6.8 mg/dL for men) increased modestly 
with increasing PFOA; the ORs by quintile of 
PFOA were 1.00, 1.33 (95% CI, 1.24–1.43), 
1.35 (95% CI, 1.26–1.45), 1.47 (95% CI, 
1.37–1.58), and 1.47 (95% CI, 1.37–1.58; 
test for trend, p < 0.0001). A positive but 
less pronounced trend was seen for PFOS. 
Inclusion of both correlated fluorocarbons in 
the model indicated that PFOA was a more 
important predictor than was PFOS. Inclusion 
of albumin in the model, which binds with 
PFOA, had little effect on these results.
The overall strength of association between 
PFOA and uric acid is modest in both the 
Steenland et al. (2010) and Costa et al. (2009) 
studies. Causality cannot be inferred from 
these cross-sectional data. There are mech-
anisms by which reverse causality might be 
applicable. For example, uric acid and PFOA 
may share renal transport systems (organic ion 
transporters 1 and 3) governing excretion of 
each substance (Eraly et al. 2008; Nakagawa 
et al. 2008), so it is possible that if the levels 
of PFOA increase, the secretion of urate is 
decreased and therefore blood urate levels may 
secondarily increase. However, whether this 
shared transporter hypothesis is relevant in 
humans remains speculative at this point.
Cardiovascular disease. Given the find-
ings for cholesterol and uric acid noted above, 
it is reasonable to ask whether PFOA is associ-
ated with cardiovascular disease. The data on 
cardiovascular disease, however, are limited 
in quantity and quality, consisting primarily 
of mortality studies among relatively small 
cohorts of workers.
The mortality of workers (n = 6,207) 
at a DuPont plant using PFOA, who were 
employed between 1948 and 2002, has been 
studied by Leonard et al. (2008) and Sakr 
et al. (2009). Serum PFOA levels among 
all workers at this plant in 2004 averaged 
240 ng/mL, with an average of 490 ng/mL 
among workers in the PFOA areas (Sakr et al. 
2007a). Standardized mortality ratios (SMRs) 
were calculated using several different referent 
populations. SMRs for ischemic heart disease 
(IHD) compared with U.S. and state general 
populations were < 1.0, as might be expected 
because of the healthy worker effect. Sakr et al. 
(2009) conducted dose–response analyses of 
these same data using a job– exposure matrix 
(Kreckmann et al. 2009), which used job cate-
gories and measured serum levels for 1,000 
workers in 2004 to assign all cohort members 
to four quartiles of cumulative serum PFOA. 
The mean serum was 231 ng/mL. Categorical 
dose–response analyses for IHD using differ-
ent lags (0. 5, 10, 15, 20 years) and different 
methods of forming quartiles (based on case 
exposures or entire cohort exposures) showed 
no significant positive trends at the p = 0.05 
level, but the analysis using a 10-year lag and 
quartiles formed based on the PFOA distribu-
tion of the entire cohort did suggest a positive 
trend [risk ratios (RRs) = 1.0, 1.0, 1.4, and 
1.6; p for trend = 0.06].
Workers at the 3M plant in Minnesota are 
the other principal occupational cohort exposed 
to PFOA. The most recent mortality update 
of this cohort is from Lundin et al. (2009) 
(n = 3,922). Workers were divided into not 
exposed, probably exposed, and definitely 
exposed groups based on job category, with 
ranges of median serum levels in the probably 
exposed job categories of 300–1,500 ng/mL 
and in the definitely exposed job categories of 
2,600–5,200 ng/mL. Mortality by the three 
exposure groups showed rate ratios of 1.0, 1.2 
[95% confidence interval (CI), 0.9–1.7), and 
0.9 (95% CI, 0.4–2.1), with observed deaths 
of 92, 103, and only 6 in the definitely exposed 
job categories. Analyses by cumulative weighted 
years of exposure (weights for unexposed, prob-
ably exposed, and definitely exposed groups 
were 1, 30, and 100) showed rate ratios of 
1.0 (138 observed), 1.2 (95% CI, 0.9–1.8; 
42 observed), and 0.8 (95% CI, 0.5–1.2; 21 
observed). There is little or no evidence of a 
positive trend in these data. Cumulatively, the 
two studies provide insufficient data for infer-
ences regarding an association between PFOA 
and cardiovascular disease.
Finally, Melzer et al. (2010) found no 
trend in self-reported history of heart dis-
ease in data from the National Health and 
Nutrition Examination Survey (NHANES), 
after dividing PFOA serum levels into 
quartiles. These data are limited by the low 
range of exposure (background levels in the 
Table 1. Changes in cholesterol in relation to changes in PFOA levels.
Study description
Change in 
PFOA (ng/mL)
Change in  
cholesterol (mg/dL)
Slope 
(assumes linearity)a
Frisbee et al. in press Cross-sectional; 12,476 high-exposed children; mean PFOA = 69 ng/mL 400 10 0.03
Steenland et al. 2009b Cross-sectional; 46,294 high-exposed adults; mean PFOA = 80 ng/mL 340 11 0.03
Sakr et al. 2007a Cross-sectional; 1,024 workers; mean PFOA = 428 ng/mL 1,000 5 0.005
Sakr et al. 2009b Longitudinal; 454 workers; mean PFOA = 1,130 ng/mL 1,000 1 0.001
Nelson et al. 2010 Cross-sectional; 860 adults, general population; mean PFOA = 4 ng/mL 5 10 2.0
Costa et al. 2009 Longitudinal, 54 workers; mean PFOA ~ 12,000 ng/mLb NA NA 0.001
Emmett et al. 2006b Cross-sectional; 371 high-exposed adults; median PFOA, 354 ng/mL 4,000  
(estimated from slope)
22 0.006c
Olsen et al. 2000 Cross-sectional (three time points); 111, 80, and 74 
workers; mean PFOA ~ 22,000 ng/mL
~ 22,000 ~ 16 0.0007c
Olsen and Zobel 2007 Cross-sectional, 506 workers; mean PFOA = 2,210 ng/mLd NA NA 0.001
Olsen et al. 2003 Longitudinal, 174 workers; mean PFOA ~ 1,500 ng/mLb NA NA 0.001
NA, not available.
aChange in cholesterol per ng/mL change in PFOA, assuming a linear relationship, which is not always apparent in some studies. Slopes were calculated for this table from published 
data; some studies presented different results for different subsamples. bResults were presented for the log of cholesterol versus parts per million PFOA (coefficients = 0.032 and 0.028, 
respectively), prohibiting extraction of a linear slope. cNot significant at p = 0.05. dThe result presented was the coefficient relating the log of cholesterol to the log of PFOA in parts per 
million (0.0076). We have approximated a linear slope for the range 0–1,000 ng/mL by using predicted cholesterol values at those two points. 
Epidemiology of PFOA
Environmental Health Perspectives • volume 118 | number 8 | August 2010 1103
general population), the cross-sectional nature 
of the data, and the lack of validation of self-
reported data.
Cerebrovascular disease. Cerebrovascular 
disease is of interest given the findings for 
uric acid, which is related to blood pressure, a 
major determinant of cerebrovascular disease. 
(No studies directly address PFOA and blood 
pressure.) Again, however, the epidemiology 
is limited to the two principal occupational 
studies described above. Leonard et al. (2008) 
found a deficit of cerebrovascular mortality 
in comparing exposed DuPont workers with 
nonexposed DuPont workers (SMR = 0.86; 
95% CI, 0.60–1.20). Lundin et al. (2009) 
found a suggestion of a positive trend of 
stroke mortality across nonexposed, probably 
exposed, and definitely exposed job categories 
using SMRs [SMRs of 0.5 (95% CI, 0.3– 0.8), 
0.7 (0.4–1.1), and 1.6 (0.5–3.7), respectively; 
no test for trend presented]. Using a cumula-
tive measure of weighted years of exposure, the 
rate ratios were 1.0 (23 deaths), 0.6 (95% CI, 
0.2–2.2; 3 deaths), and 2.1 (95% CI, 1.0–4.6; 
9 deaths), for < 1 year, 1–5 years, and > 5 
years, respectively. Like the data for heart dis-
ease, these data are too sparse to draw any 
conclusions.
Diabetes. Diabetes is not a disease of par-
ticular interest based on animal data, but some 
epidemiologic studies have addressed this end 
point nonetheless. Leonard et al. (2008) found 
a deficit of diabetes mortality in comparing 
exposed DuPont workers with the U.S. popu-
lation but a 2-fold increase in diabetes mortal-
ity compared with other, nonexposed DuPont 
workers (SMR = 1.97; 95% CI, 1.23–2.98; 
22 deaths), arguably a more suitable compari-
son group because of the healthy worker effect. 
Similarly, in internal comparisons among 3M 
workers, Lundin et al. (2009) found an excess 
of diabetes mortality in comparing a combined 
category of probably and definitely exposed 
workers and nonexposed workers (RR = 3.7; 
95% CI, 1.4–10.1; 18 vs. 5 deaths). This find-
ing was much less pronounced using years of 
exposure weighted by a qualitative judgment 
of intensity.
Diabetes mortality is not the optimal meas-
ure for a largely nonfatal disease. MacNeil et al. 
(2009) studied diabetes prevalence in a com-
munity exposed to high levels of PFOA via 
contaminated drinking water near a DuPont 
plant. Self-reported diabetes prevalence (7.8%) 
and date of onset were collected from 54,468 
adults, who had a median serum PFOA level of 
28 ng/mL (mean = 87 ng/mL) in 2005–2006 
at the time of the survey. Overall, there was 
no relation between diabetes prevalence, either 
self-reported or validated by medical records, 
and serum PFOA as measured at the time 
of the survey. A nested case–control analy-
sis was conducted in which the population 
was restricted to participants who had at least 
20 years of continuous residence in a specific 
water district (n = 13,922), to maximize the 
likelihood that serum levels in 2005–2006 
would reflect the relative exposure of subjects 
in the past. Cases were restricted to those val-
idated by medical records and occurring in 
the 10 years before 2005 (n = 1,055). There 
was a negative trend in diabetes occurrence by 
increasing serum PFOA decile (ORs = 1.00, 
0.71, 0.60, 0.72, 0.65, 0.65, 0.87, 0.58, 0.62, 
0.72). In additional analyses, fasting serum glu-
cose showed no consistent trend by increasing 
decile of serum PFOA.
Cancer. Animal data suggest that pancrea-
tic, testicular, liver, and perhaps breast cancer 
may be related to PFOA exposure (Lau et al. 
2007). Human studies are again restricted to 
the two U.S. occupational cohorts, as well as 
one follow-up study of the general population 
in Denmark. Leonard et al. (2008) found 
no excesses for liver, pancreas, testicular, or 
breast cancer based on small numbers of 
deaths (8, 11, 1, and 2 respectively). A 2-fold 
excess of kidney cancer was observed (SMR = 
1.81; 95% CI, 0.94–3.16; 12 deaths). Lundin 
et al. (2009) similarly found no excesses of 
liver and pancreatic cancers based on small 
numbers (3 and 13 deaths, respectively) and 
did not report on testicular or kidney can-
cer. Internal analyses by job category were 
reported for three cancers (prostate, pancreas, 
bladder). Some positive trend for prostate 
cancer was found by exposure group based on 
job category [nonexposed, probably exposed, 
definitely exposed; RRs of 1.0, 3.0 (95% CI, 
0.9–9.7), and 6.6 (95% CI, 1.1–37.7), based 
on 4, 10, and 2 cases respectively. For pan-
creatic cancer, the corresponding RRs were 
1.0 and 1.7 (95% CI, 0.5–4.8), respectively, 
for nonexposed and for combined probable/
definite exposure groups. The data from both 
occupational cohorts are clearly quite sparse 
and prohibit any firm conclusions.
There is also a study of 55,053 Danish 
adults 50–65 years of age who were followed 
from enrollment in 1993–1997 until 2006 
through linkage with the Danish cancer reg-
istry (Eriksen et al. 2009). There were 713, 
332, 128, and 67 incident cases of prostate, 
bladder, pancreatic, and liver cancers found 
in this period. A case–cohort approach was 
used. Dividing the population into quartiles of 
serum PFOA (based on the cases), no signifi-
cant linear trends by quartile were seen for any 
of the four cancers studied, although modest 
positive associations with prostate and pan-
creas cancers were reported [RR for highest 
quartile vs. lowest quartile: prostate cancer, 
1.18 (95% CI, 0.84–1.65); pancreatic cancer, 
1.55 (95% CI, 0.85–2.80)]. Trends were of 
borderline significance for prostate cancer and 
pancreatic cancer and were absent or nega-
tive for bladder and liver cancer. Findings for 
PFOS largely paralleled those for PFOA, which 
is not surprising given that the Spearman cor-
relation between the two was 0.80. This study, 
although much larger than the occupational 
studies cited above, had much lower ranges of 
PFOA exposure (mean = 6–7 ng/mL), typical 
of a general population.
Immune, Thyroid, Liver, 
and Kidney Function and 
Sex Hormones
Immune function. Animal studies have demon-
strated that PFOA causes lymphoid organ atro-
phy and decreased de novo antibody production 
in certain strains of mice (DeWitt et al. 2008; 
Yang et al. 2000). Total doses received in the 
Dewitt et al. (2008) study appear to have been 
about an order of magnitude higher than the 
total lifetime dose received by people drink-
ing water contaminated with 1 ng/mL PFOA. 
There appears to be strain as well as species sen-
sitivity to the immunotoxic effects of PFOA, 
with rats being considerably less sensitive than 
mice (Loveless et al. 2008), leading some to 
question the relevance of these data to humans. 
Immunotoxicity by PFOA in rodents appears 
to occur both through and independent of 
peroxisome proliferation (Yang et al. 2000). 
Immunosuppression, at least in part, occurs 
in exposed mice lacking the PPARα receptor 
(DeWitt et al. 2009). There is also evidence 
from animal studies that PFOA can suppress 
inflammatory responses (Taylor et al. 2006), 
which is similar to the effects of other PPAR 
agonists (DeWitt et al. 2009).
Human studies to date are very limited 
and have included only relatively insensitive 
test measures, such as white blood cell count 
or serum immunoglobulin (Ig) levels. Emmett 
et al. (2006a) examined the effects on PFOA 
on hematologic parameters in a cross-sectional 
community study composed of residents who 
lived in a contaminated water district for at 
least 2 years and a smaller group of volun-
teers who met the same eligibility criteria 
(Emmett et al. 2006b). They found no associ-
ation between serum PFOA and lymphocytes, 
neutrophils, eosinophils, or basophils. There 
was one small statistically significant associa-
tion between PFOA and absolute monocyte 
counts; elevated numbers of monocytes are 
often associated with recent infection, which 
was not controlled in the analysis.
Costa et al. (2009) measured serum levels 
of IgG, IgM, and IgA in 34 male workers 
engaged in the production of PFOA. Almost 
13% of the workers showed levels of serum 
IgA outside the laboratory referent values. 
Because of the small population and lack of 
controls, it is difficult to draw any conclusions 
from these data. Furthermore, the levels of 
serum Igs, which represent circulating anti-
bodies, are extremely variable in the popu-
lation and relatively insensitive markers for 
immune system effects.
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Overall human studies are insufficient for 
assessing whether PFOA is or is not related to 
immune suppression.
Thyroid function. After experimental evi-
dence of PFCs reducing T3 and T4 in rats and 
monkeys (Butenhoff et al. 2002; Lau et al. 
2007), a number of occupational and com-
munity studies have investigated these clinical 
markers of thyroid function, usually in cross-
sectional studies. Emmett et al. (2006b) inves-
tigated the association between PFOA and 
health outcomes in 371 community residents 
with high serum levels (median, 534 ng/mL) 
due to contaminated drinking water. No sig-
nificant association was found between TSH 
and the serum level of PFOA. In a small com-
munity study (n = 31) of New York State 
anglers, at much lower exposure levels (PFOA 
serum geometric mean = 1.33 ng/mL), poten-
tial associations were investigated between 
serum concentrations of eight measured PFCs 
and levels of TSH and free T4 (Bloom et al. 
2010). No associations were found, but study 
power was very low.
Olsen et al. (2003) conducted a cross-
sectional analysis that included two plants 
with 255 and 263 workers, respectively. 
Multivariate regression analysis by quartiles 
of PFOA or PFOS exposure showed no sig-
nificant association of either compound with 
T3, T4, or TSH. A continuous regression sug-
gested a slight positive association between 
log PFOA and log T3 (coefficient = 0.016, 
p-value = 0.01); however, the contribution of 
this association to the variance of the outcome 
was negligible (partial R2 = 0.01). A longitu-
dinal analysis of up to three examinations for 
174 workers from the same company found 
no association between PFOA and thyroid 
hormones (Olsen et al. 2003).
In a more recent occupational study, 
Olsen and Zobel (2007) reported on analyses 
of thyroid hormones in relation to PFOA 
among 552 employees in three plants (median 
serum level, 1,100 ng/mL). A log–log regres-
sion adjusted for age, body mass index (BMI), 
and alcohol intake showed a negative slope 
for free T4 (p = 0.01) and positive slope for 
T3 (p = 0.05), with consistent direction of 
effect for each plant. For total T4 and TSH, 
correlations across plants and within plants 
were not significant.
A recent cross-sectional analysis of self-
reported thyroid disease in the NHANES in 
relation to either PFOA or PFOS reported a 
significant association for PFOA in females, 
and a similar but much less precise associa-
tion in males, but no association for PFOS 
(Melzer et al. 2010). The OR for females of 
ever having had thyroid disease for the upper 
quartile of PFOA serum levels was 1.64 
(95% CI, 1.09–2.46) compared with the first 
quartile, and for current thyroid disease plus 
thyroid hormone medication the equivalent 
OR was 1.86 (95% CI, 1.12–3.09). For men 
the respective findings were 1.58 (95% CI, 
0.74–3.39) and 1.89 (95% CI, 0.60–5.90). 
These findings are striking given the very low 
exposures compared with the occupational 
studies, but the study suffers from using 
self-reported diagnoses, having no thyroid 
hormone data, having no exposure data at 
the time of diagnosis, and not distinguishing 
between hypo- and hyper thyroidism. In addi-
tion, there is some concern that the disease or 
treatment of disease may affect serum levels 
of PFOA.
Overall, the occupational data at high 
exposure levels show no consistent evidence of 
a reduction of thyroid hormone. In addition 
associations between T3 and T4 measured by 
the more common analog methods need to be 
treated with some caution because free T4 assay 
results have been reported to be affected by the 
presence of PFOS, which can lead to apparent 
positive associations (Chang et al. 2007). It 
is not known whether this is a problem with 
PFOA as well. Two community studies at 
lower exposure levels did not indicate an effect, 
but study sizes were small. The NHANES data 
show a strong effect on self-reported thyroid 
disease at very low levels, not easily interpreted 
in the context of the other studies.
Sex hormones. Increases in estradiol and 
decreases in testosterone with PFOA expo-
sure have been observed in rodents (Lau 
et al. 2007). However, there are very limited 
human data on hormones in relation to serum 
PFOA, found in three occupational cross-
sectional studies. Olsen et al. (1998) studied 
191 male workers divided into four exposure 
groups and measured estradiol, 17-hydroxy-
progesterone, prolactin, and bound testos-
terone. No significant associations between 
exposure and these hormones were found, but 
most of the population were in the two lowest 
exposure groups (< 1 and < 10 ng/mL), with 
only five subjects in the > 30 group. Costa 
et al. (2009) reported a multivariate regres-
sion of estradiol and testosterone in relation 
to PFOA in a group of 56 workers followed 
in routine occupational surveillance, in which 
there were no associations of sex hormones 
with serum PFOA. Finally, Sakr et al. (2007a) 
found a significant association between serum 
PFOA and both estradiol and testosterone 
in men (n = 782) in linear regression models 
(regression coefficients = 22.3 and 0.6, respec-
tively; p-values = 0.017 and 0.034, respec-
tively). Apparently there were no significant 
findings for hormones in the 243 women.
Liver function. Studies of the distribution 
of PFOA in rodents have found relatively high 
concentrations in the liver. Increased liver 
weight has been found in rodents and non-
human primates exposed experimentally to 
PFOA (Lau et. at 2007). In rodents, but not 
necessarily in primates, liver toxicity is related 
to the PPARα mode of action. However, the 
nonhuman primate studies and the evidence 
of toxicity in PPAR-null mice suggest that 
liver toxicity via other modes of action may 
be relevant, including other nuclear receptors 
in the liver (Dewitt et al. 2009; Ren et al. 
2009). The animal findings on liver toxicity 
have prompted a number of studies of liver 
enzymes in people exposed to PFOA.
Emmett et al. (2006b) reported on the 
association between serum levels and several 
liver enzymes in serum among 371 commu-
nity residents who were exposed to PFOA 
(median exposure, 354 ng/mL). Enzymes 
included alkaline phosphatase (ALP), aspar-
tate aminotransferase (AST), alanine amino-
transferase (also known as serum glutamic 
pyruvic transaminase), and gamma glutamyl 
transpeptidase (GGT). No correlations of 
serum PFOA and enzymes approached statis-
tical significance. One of the comparisons for 
abnormal values (AST; abnormal not defined) 
was associated with PFOA, but the normal 
group had higher PFOA, suggesting a protec-
tive rather than a harmful effect of PFOA.
Costa et al. (2009) reported on a surveil-
lance program of workers in a PFOA plant. 
Bilirubin and four liver enzymes showed no 
associations in cross-sectional analyses, but 
in a longitudinal analysis (n = 56) all four 
enzymes indicated a positive slope of increas-
ing enzyme levels with respect to PFOA, three 
with p-values < 0.05 [alanine transaminase 
(ALT), GGT, and ALP] and one (AST) not 
significant. Results are presented in terms of 
regression coefficients for log-transformed 
variables, which are sometimes hard to inter-
pret in terms of strength of effect. Total bili-
rubin fell with increasing PFOA (p < 0.01).
Sakr et al. (2007b), in a longitudinal study 
of liver enzymes in an occupational population 
(n = 454; mean serum PFOA = 1,130 ng/mL), 
found significant associations with AST (0.35 
units increase per 1,000 ng/mL PFOA; 95% 
CI, 0.10–0.60). Total bilirubin declined with 
increasing PFOA (0.008 mg/L decline per 
1,000 ng/mL; 95% CI, –0.0139 to –0.0021). 
In each of these cases, the change was small 
compared with the mean and standard devia-
tion of these clinical markers.
Sakr et al. (2007a) also conducted a cross-
sectional study at the same plant of PFOA, 
lipids, and liver enzymes, in 1,025 workers 
with potential exposure to PFOA. AST, ALT, 
and total bilirubin were not significantly asso-
ciated with the level of PFOA, but GGT was 
significantly positively associated with PFOA 
(p = 0.02). Observed increases were no longer 
significant when the analysis was restricted to 
those not on lipid-lowering medications. No 
notable change was found for the log of total 
bilirubin (Sakr et al. 2007a).
Several reports by Olsen and colleagues 
have addressed the liver enzymes AST, GGT, 
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and ALP along with bilirubin in exposed 
workers; in the most recent and extensive 
analysis, Olsen and Zobel (2007) reported 
data from 552 volunteers from three plants 
(mean serum level = 2,210 ng/mL). For the 
three plants together, there was a modest pos-
itive association for log GGT (coefficient = 
0.0326, p = 0.05) and log ALT (coefficient 
= 0.0249, p = 0.06), in a model with BMI 
but not in a model with triglycerides, but no 
evidence of an effect for ALP or AST in either 
model. However, results were inconsistent 
across plants, with these overall positive results 
derived from just of one of the four plants 
included. For bilirubin, the relationship was 
consistently negative and significantly nega-
tive overall (exposure–response coefficient: 
in model with BMI, –0.0325, p = 0.001; in 
model with triglycerides, –0.0267, p = 0.01). 
These positive findings contrast with earlier 
cross-sectional analyses of these plants that 
were essentially negative (e.g., Gilliland and 
Mandel 1996; Olsen et al. 1999).
Lin et al. (2010) assessed the relationships 
between ALT, GGT, and bilirubin and four 
PFCs, including PFOS and PFOA, meas-
ured in serum in the NHANES surveys of 
1999–2000 and 2003–2004 (n = 2,216). They 
found significant trends for liver enzymes 
across quartiles of PFOA and in regressions 
of log-transformed enzyme levels against log-
transformed PFOA. However exposure con-
trasts were low, with the lowest quartile < 2.9 
and the top quartile > 5.95 ng/mL PFOA. 
Given these small exposure contrasts, the 
models suggested a much larger effect per unit 
exposure than did other studies.
In summary, studies of liver enzymes have 
reported some associations with PFOA. Four 
independent studies (two longitudinal and 
two cross-sectional studies) reported reduced 
bilirubin associated with increasing PFOA, 
and at least two studies showed results sug-
gesting increasing AST or GGT in relation to 
PFOA. However, the changes in liver enzymes 
are quite small, and the magnitude of effect 
is quite inconsistent, with results from the 
NHANES study showing an effect of expo-
sure going from 1 to 3 ng/mL, whereas other 
studies looked at contrasts of thousands of 
nanograms per milliliter of PFOA, in some 
cases with no apparent association. These 
results provide limited evidence of some bio-
logical activity of PFOA in human liver, the 
clinical significance of which is uncertain.
Kidney function. PFOA concentrates 
in the kidney in animals and therefore is of 
interest as a potential target organ. However, 
no animal data document kidney toxicity, 
and human data are also quite limited.
In an occupational study, Costa et al. 
(2009) reported no significant associa-
tion between PFOA and either urea nitro-
gen or creatinine. These negative results 
were consistent with those of Emmett et al. 
(2006b), who found no significant association 
between either blood urea nitrogen or creati-
nine with the serum level of PFOA.
Reproductive and 
Developmental Outcomes
Toxicology studies indicate the potential for 
PFOA and PFOS to affect fetal growth and 
development. In utero exposure to PFCs is 
associated with a range of nonspecific adverse 
developmental outcomes in mouse, rat, and 
rabbit models (Lau et al. 2007; Olsen et al. 
2009), including reduced fetal weight and 
increased neonatal mortality. Extrapolation 
across species and end points is particularly 
problematic in reproductive toxicology.
Epidemiologic research on PFOA and 
reproductive end points was initiated quite 
recently, with most studies published in 2007 
or later (Olsen et al. 2009). With few excep-
tions, the studies examine serum PFOA in 
relation to the risks of a range of different 
adverse outcomes. Except for fetal growth, 
most of the end points have been examined in 
only one or two studies.
Starting with fertility, one study of semen 
quality and reproductive hormones in men 
(Joensen et al. 2009) reported decrements 
in sperm count and number of morphologi-
cally normal sperm with higher exposure to 
the combined level of PFOA and PFOS, 
but weaker associations with PFOA alone. 
An integrated measure of couple fecundity, 
time to pregnancy, was examined by Fei et al. 
(2009). This same population was examined 
for several other reproductive end points and 
thus warrants a more extensive description.
Starting with > 100,000 participants in 
the Danish National Birth Cohort, which 
recruited women from 1996 to 2002 and 
followed women through the course of 
pregnancy and continued with childhood 
assessment, Fei et al. (2009) randomly 
selected 1,400 women with singleton live 
births for measurement of PFOA and PFOS 
in blood collected during the first trimester 
of pregnancy (mean PFOA = 5.6 ng/mL). 
The evalua tion of time to pregnancy showed 
increased risk of irregular menstrual cycles 
in the upper three quartiles of PFOA rela-
tive to the lowest quartile (15.0% vs. 9.0%) 
and an increase in mean PFOA with increas-
ing time required to conceive (5.4 ng/mL 
for < 6 months to conception, 6.0 ng/mL for 
6–12 months to conception, and 6.3 ng/mL 
for > 12 months to conception). The odds of 
infertility (≥ 12 months without conception) 
were elevated in the upper three quartiles of 
PFOA exposure (ORs ranging from 1.6 to 
2.5) relative to the lowest quartile. Very sim-
ilar patterns were reported for PFOS. The 
absence of dose–response gradients for fertility 
across levels suggests the possibility of some 
peculiarity in the lowest exposure group but 
does not preclude a causal relationship with a 
maximum effect at a very low exposure level.
The course of pregnancy, including risk 
of miscarriage and preeclampsia, has been 
addressed in a study of a subset of women 
exposed to markedly elevated levels of PFOA 
in the Mid-Ohio Valley (Stein et al. 2009). 
No association was found between PFOA 
and miscarriage, whereas a weak association 
was found for preeclampsia (for above-me-
dian exposure to PFOA: OR = 1.3; 95% CI, 
0.9–1.9). Nolan et al. (2009a) used birth cer-
tificate information to address pregnancy com-
plications in women residing in a high-PFOA 
area of the Mid-Ohio Valley and reported 
extremely imprecise associations with anemia 
and dysfunctional labor and lower overall risk 
of labor and delivery complications.
The most extensive set of studies has exam-
ined fetal growth, birth weight, duration of 
gestation, and related indices of in utero devel-
opment. Seven studies reported continuous 
measures of birth weight in relation to contin-
uous measures of PFOA exposure (Apelberg 
et al. 2007; Fei et al. 2007; Hamm et al. 2009; 
Inoue et al. 2004; Monroy et al. 2008; So 
et al. 2006; Washino et al. 2009). Two studies 
of background exposure to PFOA reported 
clear evidence of decreased birth weight in 
relation to increased PFOA (Apelberg et al. 
2007; Fei et al. 2007), with smaller decre-
ments reported in two other studies of back-
ground exposure levels (Hamm et al. 2009; 
Washino et al. 2009). Magnitude of associa-
tion ranged from a decrement of 37 to 104 g 
per log unit increase in PFOA exposure, 
with varying degrees of statistical precision, 
with one study (Fei et al. 2007) reporting a 
smaller reduction of 10.6 g per ng/mL PFOA. 
Three smaller studies reported no association 
between PFOA and birth weight (Inoue et al. 
2004; Monroy et al. 2008; So et al. 2006). 
Risk of low birth weight (< 2,500 g) was ele-
vated in the upper three quartiles relative to 
the first quartile in the analysis of the Danish 
National Birth Cohort (Fei et al. 2007), but 
a measure of small-for-gestational-age (which 
accounts for duration of gestation) was not 
related to PFOA in the Danish National Birth 
Cohort (Fei et al. 2007) nor in a study from 
Alberta, Canada (Hamm et al. 2009). An eco-
logic study of residence and birth weight in 
the Mid-Ohio Valley found no association 
between PFOA exposure and birth weight 
(Nolan et al. 2009b). Stein et al. (2009) did 
not find an association between PFOA and 
self-reported low birth weight.
Cumulatively, the studies provide incon-
sistent suggestions of a possible decrement in 
birth weight associated with PFOA exposure, 
with studies varying in whether the association 
with PFOS is similar (Apelberg et al. 2007), 
stronger (Stein et al. 2009; Washino et al. 
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2009), or weaker (Fei et al. 2009; Hamm 
et al. 2009) than that reported for PFOA. 
Different measures of fetal growth across stud-
ies make it difficult to assess whether the stud-
ies of background PFOA and those addressing 
more elevated PFOA levels are consistent with 
one another, but thus far the positive evidence 
for an effect on birth weight comes from stud-
ies of background exposure levels. Although 
an adverse impact of PFOA on birth weight 
would be of some concern in suggesting sensi-
tivity of the fetus, shifts of the reported mag-
nitudes within the normal birth weight range 
are of little or no clinical significance.
Other indices of fetal growth have been 
examined in isolated studies with sugges-
tions of adverse effects of PFOA on head cir-
cumference and ponderal index (Apelberg 
et al. 2007) and on abdominal circumference 
and birth length (Fei et al. 2008b). Studies 
addressing preterm birth reported elevated 
risks for intermediate exposure categories only 
(Fei et al. 2007) or no association (Hamm 
et al. 2009; Stein et al. 2009).
Child health and development have been 
examined to a very limited extent. Stein et al. 
(2009) reported an association between PFOA 
levels exceeding the 90th percentile and birth 
defects in aggregate (OR = 1.7; 95% CI, = 
0.8–3.6). Birth defects in aggregate were not 
associated with residence in a high-PFOA 
area of the Mid-Ohio Valley in a study based 
on birth certificates (Nolan et al. 2009a). 
Fei et al. (2008a) examined parent-reported 
developmental milestones in infants 6 and 
18 months of age and found no indication of 
delays associated with higher PFOA exposure.
Discussion
Although the epidemiologic literature on the 
health effects of PFOA is growing rapidly, 
overall it remains limited in volume and qual-
ity. Many studies are cross-sectional in nature, 
making causal inference difficult. Other stud-
ies are small and have too few outcome events 
to draw firm conclusions. The range of PFOA 
varies greatly in different populations studied, 
with some studies of biomarkers identifying 
effects at low general population levels and 
others with a much higher and large range of 
exposures finding smaller or no effects.
The most consistent findings have been 
for modest increases in cholesterol, and to 
a lesser degree for a modest increase in uric 
acid, among those with higher PFOA levels. 
However, these findings have been largely 
based on cross-sectional data (exposure and 
outcome measured simultaneously), calling 
into question whether the relationship is causal. 
Three longitudinal studies show that PFOA 
changes over time correlate with changes in 
cholesterol levels (Costa et al. 2009; Olsen 
et al. 2003; Sakr et al. 2007b), and one longi-
tudinal study shows a similar effect on uric acid 
(Costa et al. 2009). These longitudinal studies 
strengthen the case for a causal relationship, 
although they do not necessarily preclude that 
PFOA and cholesterol, or PFOA and uric acid, 
are both associated with some other biologi-
cal process that is changing over time. Other 
cross-sectional findings show some evidence 
of an increase in liver enzymes with higher 
serum PFOA, but these findings have not been 
consistent across studies, and observed enzyme 
increases have been modest.
Cohorts followed for mortality have the 
potential to shed more light on the occurrence 
of chronic disease. There have been only two 
of these, both occupational (Leonard et al. 
2008; Lundin et al. 2009). Findings in these 
two cohorts have not been consistent, with 
the exception of diabetes mortality, which 
was significantly elevated in both studies 
when worker comparison groups were used. 
However, a large study of diabetes prevalence, 
a more sensitive outcome, using retrospective 
exposure estimates, showed no relation with 
PFOA (MacNeil et al. 2009). Other findings 
from the occupational cohort mortality stud-
ies have been inconsistent, with excesses in 
one but not the other. There is some evidence 
of increased kidney cancer and heart disease 
in one cohort (Leonard et al. 2008; Sakr et al. 
2009), whereas stroke and prostate cancer 
showed a positive exposure–response trend in 
the other (Lundin et al. 2009). All these find-
ings (except for the heart disease finding) were 
based on small numbers of deaths. Another 
nonoccupational cohort, with much lower 
exposure levels, has been followed for can-
cer in Denmark, with no significant excesses 
observed (Eriksen et al. 2009). In summary 
then, for chronic disease, sparse and inconsis-
tent evidence prohibits any conclusions.
The research on reproductive and develop-
mental health end points is expanding rapidly 
and offers sporadic evidence that is difficult to 
interpret. A range of indicators of fetal devel-
opment, including birth weight, may be sub-
tly affected by relatively low levels of PFOA, 
but the potential for an artifactual relationship 
with PFOA metabolism cannot be discounted 
(Savitz 2007). Furthermore, the associations, 
although often statistically significant, are 
quite small in absolute terms and of limited 
direct clinical significance. Other studies that 
address more clinically consequential out-
comes report null or marginal adverse effects, 
with none replicated in independent studies 
at this time.
In summary, the epidemiologic evi-
dence accumulated thus far on health effects 
of PFOA comes principally from two occu-
pational cohorts and several occupational 
cross-sectional studies, as well as community 
populations with background exposure levels, 
and one community with elevated exposure in 
the Mid-Ohio Valley.
Although the occupational studies have 
the advantage of substantially elevated expo-
sure ranges, they suffer from several limita-
tions. They are primarily limited to males. 
The cohort mortality data are limited for rare 
diseases and those that are typically not fatal. 
The prevalence studies measure subclinical 
end points, typically blood chemistry, and are 
limited for causal inference and are of variable 
clinical significance.
The community studies of populations with 
background exposures are more broadly repre-
sentative of the general population, but it is 
difficult to discern clear associations within the 
limited exposure range available to study. In 
contrast to these important but inherently lim-
ited sources of epidemiologic information, we 
are pursuing an unusual opportunity to extend 
our knowledge regarding the health effects of 
PFOA considerably by conducting a series 
of studies of an exposed community popu-
lation in the Mid-Ohio Valley (Frisbee et al. 
2009) (see http://www.c8sciencepanel.org for a 
description of the studies currently under way). 
Levels of PFOA exposure in this population are 
markedly above background (median values 
were 5 times background but included a wide 
range; mean levels were 15 times background), 
although still below occupational levels (which 
often have mean levels 200 times background). 
The population is large (> 60,000 individu-
als) and comprises a wide age range (including 
children). In addition, we are also studying 
disease incidence in a cohort of approximately 
6,000 workers with much higher levels (e.g., 
levels of 1,000 ng/mL, 200 times background). 
[Leonard et al. (2008) studied this same cohort 
for mortality.] Although there are method-
ologic challenges in this setting as well, par-
ticularly in reconstructing historical exposure 
levels and in ascertaining health end points 
accurately, these studies should provide new 
evidence complementary to that which has 
been generated to this point. To the extent 
that there are other such communities around 
the world that are exposed to elevated levels 
of PFOA due to a point source, epidemiologic 
research in those settings would be of clear 
value and help to evaluate the consistency of 
future findings in the Mid-Ohio Valley.
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